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It is known that human hemoglobin contains low levels of N-terminal N-(2-hydroxyethyl)valine.
Possible sources of this modified amino acid are exposure to ethylene oxide or other 2-hydroxy-
ethylating agents. Although such processes are likely to occur endogenously, the exogenous
contribution to the adduct formation is unclear. In order to explore the latter, we have analyzed
N-(2-hydroxyethyl)valine in the globin of 49 pregnant women and evaluated the effect of smoking
status, area of residence, and glutathione S-transferase Ml genotype on adduct levels.
Transplacental transfer of hydroxyethylating agents was also studied by the analysis of umbilical
cord hemoglobin. The adduct levels in smokers were significantly higherthan those in nonsmokers.
The adduct levels in umbilical cord blood globin were quantitatively related to those in maternal
blood (maternal:fetal ratio 2.7 in smokers and 2.8 in nonsmokers). In the nonsmokers, there was
no statistically significant difference in the adduct level between the urban and rural areas, but the
level in suburbia tended to be lower than that in the rural area. In the combined smoker and
nonsmoker groups, there was no effect of the glutathione S-transferase Ml genotype on levels
of N-(2-hydroxyethyl)valine. Environ Health Perspect 104(Suppl 3):449-452 (1996)
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Introduction
In recent years considerable emphasis has
been placed on the development ofmeth-
ods for the qualitative and quantitative
detection ofadducts ofcarcinogens with
nucleic acids and proteins (especially hemo-
globin and albumin) (1,2). The relation-
ship between adducts measured on proteins
and adducts on DNA is variable according
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to carcinogen, exposure conditions, etc.;
however, for many compounds, there
appears to be a proportionality between
protein adducts and DNA adducts, espe-
cially at lowdoses ofcarcinogen.
It has been a significant discovery that
adducts for many carcinogens have been
found in supposedly unexposed popula-
tions (3). This is particularly apparent for
low molecular weight alkyl adducts and for
hydroxyl radical damage. A well-studied
example of this is the adducts produced
following exposure to ethylene oxide (EO).
These adducts contain 2-hydroxyethyl
groups attached to nucleophilic centers
within DNA or protein. Such hydrox-
yethyl adducts may also be produced fol-
lowing exposure to avariety ofother agents
(e.g., 2-chloroethanol, 2-hydroxyethyl dia-
zonium ion), or they could arise through
degradation ofother chemically unstable
adducts (e.g., 2-chloroethyl adducts).
The major interaction product ofEO
with DNA is N-7-(2-hydroxyethyl)guanine
(7-HEG) (4). This may be released from
DNA by thermal hydrolysis and analyzed
byhigh performance liquidchromatography
(HPLC) with fluorescence detection (5) or
by gas chromatography-high resolution
mass spectrometry (GC-MS)(6). Using
these procedures, dose-response relation-
ships have been determined in rats and
mice following exposure to ethylene oxide
(7) and ethylene, which is metabolized to
the epoxide (6). In these studies, a back-
ground level of7-HEG was found in non-
exposed control animals (2.46 ± 1.6x 106
and 1.38 ±0.61 x 10-6 units in rat and
mouse liver DNA, respectively). The
source ofthis background level ofalkyla-
tion maybe partiallyendogenous, although
other environmental factors may play a
part in its generation.
In inhalation experiments with EO in
rats and mice, it has been shown that
adducts of this epoxide are also formed
with amino acids in hemoglobin, including
the N-terminal amino acid valine that
yields N-(2-hydroxyethyl)valine (HEV)
(Figure 1) (8). There is a relationship
between the amount of DNA adduct and
the hemoglobin adduct, but this is very
dependent upon the exposure conditions,
time of sampling, etc. (7). However,
because ofthe ready availability ofhemo-
globin in contrast to that ofDNA, consid-
erable attention has been paid to the
monitoring of the hemoglobin adducts,
e.g., HEV, as an index of exposure to
ethylene oxide.
HEV in globin may be analyzed by
GC-MS following its release from the
protein by a modified Edman degrada-
tion procedure, originally developed by
Tornqvist et al. (9). The limit ofsensitivity
ofthis assay in our hands is approximately
1 pmol HEV/g globin, which we have
shown is adequate for monitoring human
exposure to hydroxyethylating agents from
occupational or environmental sources.
Some examples of results that we have
obtained are summarized in Table 1.
Occupational exposure to EO yielded up
to 13 nmol HEV/g globin (10). Cigarette
smoking gave a dose-related increase in
HEV (-70 pmol/g globin/10 cigarettes)
(11), presumably largely due to the pres-
ence of ethylene (and a much smaller
CH3 CH3 /
CH
HOCH2CH2NH-CH CO--
Figure 1. N-(2-hydroxyethyl)valine (HEVSin globin.
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Table 1. Levels of N-(2-hydroxyethyl)valine in human globin.
Exposure N-(2-hydroxyethyl)valine References
Occupational exposure to ethylene oxide Up to 13 nmol/g globin (10)
Cigarette smoking -70 pmol/g/lO cigarettes (11)
-40% Maternal adduct level in
newborn children of smokers (12)
Fotemustine (90 mg/m2) 300 pmol/g globin (13)
Controls 50 pmol/g globin (11)
30 pmol/g globin (14)
22 pmol/g globin (16)
amount ofEO) in the smoke. We have also
demonstrated that HEVlevels are enhanced
in the globin ofbabies ofsmoking mothers
compared to those of nonsmoking moth-
ers, illustrating that there is transplacental
transfer of the alkylating species or its
metabolic precursor. The level ofadducts
in the babies' globin was related to that in
the mothers' globin, at a ratio of 1:2.5
(12). The anticancer drugs, 2-chloroethyl-
nitrosoureas (e.g., tauromustine, nimus-
tine, fotemustine) are believed to yield
2-chloroethyl diazonium ions in vivo, and
patients treated with these agents contain
elevated levels ofHEV in their globin (13).
Ofparticular interest in these studies is
that supposedly unexposed individuals
contained background levels of HEV. Our
initial sudies showed this background level
to be at approximately 50 pmol HEV/g
globin (11). In a more recent international
study, we compared HEV levels in the glo-
bin ofpopulations from four centers (York,
U.K.; Swansea, U.K.; Mo, Norway; and
Copenhagen, Denmark) (14). These pop-
ulations differed in their exposure to envi-
ronmental pollution. The average HEV
level in all populations combined was 29.5
pmol/g globin, but interestingly, the most
rural population, York, had levels of HEV
(35.3 ±7.6 pmol/g globin) that were signi-
ficantly higher (p<0.01) than those in the
more urban areas, Copenhagen (20.9 9.1
pmol/g globin) and Swansea (27.1 ± 6.3
pmol/g globin). Thus, there appear to be
further environmental parameters that
govern the amount of background HEV
in globin.
A further factor that may contribute to
HEV levels in globin is exposure to exhaust
fumes. Tornqvist et al. (15) demonstrated
in rats and hamsters that exposure to auto-
motive engine exhausts resulted in a dose-
related increase of HEV in globin. In a
recent study, we have demonstrated that
bus garage workers and mechanics exposed
to exhaust fumes have a higher HEV
adduct level in globin (33.3 pmol/g globin)
than a control population (22.1 pmol/g
globin) (16).
There appears to be considerable evi-
dence for background hydroxyethylation of
both DNA and hemoglobin. In the case of
hemoglobin, some environmental influ-
ences have been discovered; however, a
proportion ofthe background adduct level
seems to be due to the endogenous produc-
tion of ethylene. Ethylene is exhaled by
both rats and humans, although its meta-
bolic origin is still unclear. Using an endo-
genous production rate of 32± 12 nmol
ethylene/hr, Filser et al. (17) calculate that
the endogenous background of HEV
should be 12 ±2.9 pmol/g globin. This is
considerably lower than the HEV levels in
the control nonsmoking populations that
we [and other authors (18)] have observed.
The purpose ofthis study is to extend
our knowledge on the factors that may
influence the nonendogenous contribution
to HEV levels in control globin. (Clearly
the distinction between endogenous and
exogenous exposure becomes a little hazy,
because some exogenous factors may
influence endogenous processes.) We have
now considered smoking status, area ofres-
idence, and glutathione S-transferase MI
(GSTMI) genotype. Transplacental trans-
fer ofhydroxyethylating agents was also
studied by the analysis of mothers' and
umbilical cord hemoglobin.
Methods
Sample Collection
The study cohort consisted of49 pregnant
women aged 19 to 44 years (mean 29) liv-
ing in the county ofAarhus, which includes
both rural, urban, and suburban areas. The
city ofAarhus has approximately 250,000
residents. The cohort was divided into four
groups according to smoking habits or
residence, the latter being based upon
the postal code. Group 1: nonsmoking
with residence in the city center ofAarhus
(n = 11); group 2: nonsmoking with
residence in the suburban part (n = 12);
group 3: nonsmoking with residence in
the rural areas (n =6); and group 4: smok-
ers (n =20) living in Aarhus County. None
ofthe women were occupationally exposed
to known genotoxic compounds prior
to pregnancy.
Whole blood (2 ml) was collected in
heparin tubes for DNA isolation. The
maternal blood sample was collected
shortly after delivery. All cases were
collected in the period from November
1993 to January 1994 at the Department
of Gynecology/Obstetrics at Aarhus
University Hospital. Prior to the collec-
tion, all the women gave informed consent
according to the Helsinki II declaration.
A questionnaire to assess the potential
exposure to genotoxic compounds was
administered 2 months before delivery.
Information on residence, occupation,
means of transportation, and lifestyle fac-
tors including passive smoking was
collected. Nonsmoking status was verified
by determination of cotinine in serum
samples using the cotinine EIA microplate
assay (Solar Care Technologies Corp.,
Bethlehem, PA).
GC-MSAnalysis
HEV was analyzed by GC-MS after a pro-
cedure involving a modified Edman degra-
dation of the protein, SepPak cartridge
chromatography, conversion ofthe partially
purified pentafluorophenyl thiohydantoin
ofHEV to its trimethylsilyl derivative, and
GC-MS selected ion recording. A tetradeu-
terated analogue was used as internal stan-
dard. The details of the procedure have
been published previously (13).
Determination of GSTM1 Genotype
The maternal GSTM1 was determined by
a slight modification of the procedure
described by Zhong et al. (19) using DNA
isolated from whole blood. Three oligonu-
cleotide primers, P1 (5'-CGCCATCTTG
TGCTACATTGCCCG-3'), P2 (5'-ATC
TTCTCCTCTTCTGTCTC-3') and P3
(5'-TTCTGGATTGTAGCAGATCA-3'),
were used to identify the GSTM1 geno-
type. The P1 and P2 primers can anneal
to either the GSTM1 or the GSTM4 gene
and yield a 157 bp polymerase chain reac-
tion (PCR) product, whereas the P3
primer anneals specifically to the GSTM1
gene. The P1/P3 PCR product is a 230 bp
long GSTM1 specific fragment. The
GSTM1+ genotype will have both PCR
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products, while the GSTMI- will have
only one product.
StatisticalAnysis
The Mann-Whitney two-tailed test was
used to compare the adduct levels in the
different groups and to evaluate associa-
tions between adduct levels and potential
source ofexposure; the Kruskal-Wallis test
was used to evaluate the effect of the
GSTMI genotype on the adduct level.
Results
HEVwas determined in maternal and fetal
blood from 49 subjects, and the compara-
tive results are depicted in Figure 2. There
was a linear relationship between HEV in
hemoglobin in mothers and in umbilical
cords (0.9329 linear regression, slope
2.827, intercept 10.11). The adduct levels
in smokers are significantly higher than in
the nonsmoking group (p=0.000, Mann-
Whitney), (Table 2), and the placenta
provides some protection. The maternal:
fetal mean ratio is 2.7 in smokers and 2.8
in nonsmokers.
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Figure 2. Relationship between N-(
ethyl)valine levels in globin from materr
blood (pmol/g globin).
Table 2. N-(2-hydroxyethyl)valine adduct
on place of residence and cigarette smokir
Median HEV a(
(number of
Test groups Mother
Smokers 150.9(20)
Nonsmokers 30.3 (29)
Urban 28.1 (11)
Suburban 27.4(12)
Rural 37.4(6)
ND, not determined. Statistical evaluatio
nonsmoker, p=0.0000; urban vs suburbai
urban vs rural, p=0.2087; suburban vs rura
Table 2 shows the effect ofthe residen-
tial living area on the HEV levels in the
mothers' globin. There was no statistically
significant difference in the adduct level
between the urban and rural areas, but the
level in suburbia tends to be lower than that
in the rural area (p=0.1462) (Figure 3).
The genotype of GSTM1 was deter-
mined by a PCR-based assay to test the
null genotype. Overall, 54.9% ofthe whole
population was negative for the GSTMI
genotype. There were 47.6% negative
smokers and 58.6% negative nonsmokers.
The GSTMI genotype did not seem to have
any significant effect on the HEV adduct
level in globin in the nonsmoker and
smoker groups combined in which the
median value was 37.4 pmol/g globin in the
null group and 44.1 pmol/g in the GSTMI-
positive group. However, in the smoker
group, a tendency toward a higher level
was observed in the null group (median
value 150.9 pmol/g globin compared to
139.1 pmol/g globin in the GSTMI-posi-
tive group). The number of samples was
insufficient for a statistical evaluation.
Discussion
The results further support the premise that
environmental factors have a modifying
effect on HEV levels in globin. Ofparticu-
lar interest was the observation that rural
dwellers had higher adduct levels than sub-
urban dwellers, despite the fact that we had
previously shown that exposure to exhaust
- fumes positively contributes to HEV levels.
200 250 A similar observation was made for the
polycyclic aromatic hydrocarbon (PAH)-
albumin adduct, which was measured using
(2-hydroxy- a competitive enzyme-linked immunoad-
nal and cord sorbent assay (ELISA) technique in the
same population (20). The reason for the
greater hydroxyethylating agent exposure
levels based in the countryside is unknown. One postu-
lg. late is that it is due to the source ofheating
dduct level in these areas-commonly oil, wood or
cases) straw-in contrast to the community-
Child based heating systems in urban areas.
55.2(20) Combustion ofwood and straw is known
7.3(25) to generate mutagenic compounds.
ND Cigarette smoking has again been
ND demonstrated in this study to be a contri-
ND buting source of HEV in globin. Trans-
)n: smoker vs placental transfer ofthe hydroxyethylating
n, p=0.8535; agent, or of a compound (e.g., ethylene)
31,p=0.1462. that could generate it after activation by
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Figure 3. Effect of area of residence on N-(2-hydroxy-
ethyl)valine (HEV) adduct levels in nonsmokers' globin.
The boxes represent the range for 75% of the results.
*Median.
placental microsomes, was shown to occur.
The maternal:fetal ratio of the smoking
population was 2.7, which is similar to the
ratio previously observed (2.5) on a smaller
population in which levels of HEV in
mothers' globin were compared to those in
the globin of their newborns (12). More
than halfofthe hemoglobin ofthe newborn
is hemoglobin F, whose N-terminal valine
content is only 50% ofthat ofadult hemo-
globin; therefore, alower adduct levelwould
be expected in the newborn. In contrast to
the 2.5- to 2.7-fold ratio for adult:fetal
adduct levels ofHEV, the PAH-albumin
adduct level was only 1.3 times greater in
smoking mothers' blood compared to that
in the umbilical cord blood (20).
Glutathione transferase is directly
involved in the conjugation and consequent
detoxification of a variety of epoxides; it
has been postulated that populations
deficient in GSTMI activity may be at a
potential higher risk of genotoxicity when
exposed to these epoxides (21). However,
in the present study, the GSTMI genotype
did not seem to be related to HEV adduct
levels at low exposure situations, although
it is possible that it may have a slight effect
at high exposures (e.g., cigarette smoking).
A similar observation was made for the
PAH-albumin levels (20).
It may be concluded that both
endogenous and exogenous factors con-
tribute to the 2'-hydroxyethylation of
hemoglobin and presumably DNA. The
extent ofthis background alkylation is rela-
tively large compared with many other
covalent modifications that have been
studied, and its mutagenic/carcinogenic
significance, although unknown, should
not be underestimated.
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